ICU MEDICAL ENTREPRISE FRANCE SAS : revenue, balance sheet and financial ratios

ICU MEDICAL ENTREPRISE FRANCE SAS is a French company founded 36 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in RUNGIS (94150), this company of category PME shows in 2024 a revenue of 25.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Historique financier - ICU MEDICAL ENTREPRISE FRANCE SAS (SIREN 353021827)
Kennzahl 2024 2023 2022 2021 2020 2019 2018 2017
Umsatz 25 693 198 € 24 990 694 € 36 593 620 € 33 637 893 € 36 077 127 € 35 147 192 € 33 528 491 € 33 153 689 €
Nettoergebnis 1 321 931 € 744 612 € 1 124 389 € 607 764 € -2 135 097 € 1 114 173 € -35 166 € -1 447 997 €
EBITDA 793 769 € 715 641 € 1 629 571 € 2 225 531 € 2 525 407 € 2 309 535 € 711 101 € 2 945 112 €
Nettomarge 5.1% 3.0% 3.1% 1.8% -5.9% 3.2% -0.1% -4.4%

Umsatz und Gewinn- und Verlustrechnung

In 2024, ICU MEDICAL ENTREPRISE FRANCE SAS achieves revenue of 25.7 M€. Activity remains stable over the period (CAGR: -3.6%). Vs 2023: +3%. After deducting consumption (17.8 M€), gross margin stands at 7.9 M€, i.e. a rate of 31%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 794 k€, representing 3.1% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 1.3 M€, i.e. 5.1% of revenue. This profit can be retained or distributed to shareholders.

Umsatz (2024) ?
Umsatz
Definition
Gesamtbetrag der Verkäufe von Waren und Dienstleistungen des Unternehmens.
Formel
Warenverkäufe + Verkaufte Produktion

25 693 198 €

Bruttomarge (2024) ?
Bruttomarge
Definition
Differenz zwischen Umsatz und Wareneinsatz.
Formel
Umsatz - Wareneinsatz

7 897 677 €

EBITDA (2024) ?
EBITDA (Betriebsergebnis vor Abschreibungen)
Definition
Ressource générée par l'activité courante, avant amortissements et charges financières.
Formel
Wertschöpfung - Personalkosten - Steuern
Interpretation
Positiv = rentable Tätigkeit

793 769 €

EBIT (2024) ?
EBIT (Betriebsergebnis)
Definition
Betriebsergebnis, einschließlich Abschreibungen und Rückstellungen.
Formel
EBITDA - Abschreibungen und Rückstellungen + Auflösungen

1 245 256 €

Nettoergebnis (2024) ?
Nettoergebnis
Definition
Bénéfice ou perte après toutes les charges, y compris impôts et éléments exceptionnels.
Formel
Ordentliches Ergebnis + Außerordentliches Ergebnis - Ertragsteuern

1 321 931 €

EBITDA-Marge (2024) ?
EBITDA-Marge
Definition
Misst die operative Rentabilität des Unternehmens.
Formel
(EBE / CA) x 100
Interpretation
> 10% : Gute Rentabilität
5-10% : Durchschnitt
< 5% : Faible

3.1%

Chargement du compte de résultat...

Évolution graphique

Anzeigen :

Aktiva

Chargement des données...

Passiva

Chargement des données...

Solvenz- und Verschuldungskennzahlen

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 58%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 3.4% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.

Verschuldungsgrad (2024) ?
Verschuldungsgrad
Definition
Misst das Verhältnis von Schulden zu Eigenkapital.
Formel
(Finanzschulden / Eigenkapital) x 100
Interpretation
< 50% : Faible
50-100% : Moderat
> 100% : Hoch

0.0%

Finanzielle Autonomie (2024) ?
Finanzielle Autonomie
Definition
Anteil des Eigenkapitals an der Gesamtfinanzierung.
Formel
(Eigenkapital / Bilanzsumme) x 100
Interpretation
> 30% : Gute Autonomie
20-30% : Durchschnitt
< 20% : Faible

57.646%

Cashflow / Umsatz (2024) ?
Cashflow / Umsatz
Definition
Capacité d'autofinancement rapportée au chiffre d'affaires.
Formel
(CAF / CA) x 100
Interpretation
Je höher das Verhältnis, desto mehr Liquidität generiert das Unternehmen

3.375%

Rückzahlungsfähigkeit (2024) ?
Rückzahlungsfähigkeit
Definition
Anzahl der Jahre zur Schuldenrückzahlung mit dem Cashflow.
Formel
Dettes financières / CAF
Interpretation
< 3 Jahre : Ausgezeichnet
3-5 Jahre : Angemessen
> 5 Jahre : Attention

0.0

Entwicklung der Solvenzkennzahlen
ICU MEDICAL ENTREPRISE FRANCE SAS

Positionnement sectoriel

Debt ratio
0.0 2024
2022
2023
2024
Q1: 0.0
Méd: 4.27
Q3: 43.96
Excellent

In 2024, the debt ratio of ICU MEDICAL ENTREPRISE FR... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
57.65% 2024
2022
2023
2024
Q1: 14.64%
Méd: 38.36%
Q3: 60.56%
Good

In 2024, the financial autonomy of ICU MEDICAL ENTREPRISE FR... (57.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
0.0 years 2024
2022
2023
2024
Q1: 0.0 years
Méd: 0.0 years
Q3: 1.09 years
Excellent

In 2024, the repayment capacity of ICU MEDICAL ENTREPRISE FR... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquiditätskennzahlen

The liquidity ratio (= Current assets / Current liabilities) stands at 277.31. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.2x. Danger: operating income does not cover interest charges, unsustainable situation.

Liquiditätsquote (2024) ?
Liquiditätsquote
Definition
Fähigkeit, kurzfristige Schulden mit dem Umlaufvermögen zu decken.
Formel
Umlaufvermögen / Kurzfristige Verbindlichkeiten
Interpretation
> 1.5 : Sehr gut
1-1.5 : Angemessen
< 1 : Risque de liquidité

277.305

Zinsdeckung (2024) ?
Zinsdeckung
Definition
Fähigkeit, Zinsaufwendungen mit dem Betriebsergebnis zu decken.
Formel
EBIT / Zinsaufwendungen
Interpretation
> 3 : Komfortabel
1.5-3 : Acceptable
< 1.5 : Risiko

0.206

Entwicklung der Liquiditätskennzahlen
ICU MEDICAL ENTREPRISE FRANCE SAS

Positionnement sectoriel

Liquidity ratio
277.31 2024
2022
2023
2024
Q1: 132.74
Méd: 202.27
Q3: 325.9
Good -7 pts über 3 Jahre

In 2024, the liquidity ratio of ICU MEDICAL ENTREPRISE FR... (277.31) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Interest coverage
0.21x 2024
2022
2023
2024
Q1: 0.0x
Méd: 0.41x
Q3: 6.25x
Average -11 pts über 3 Jahre

In 2024, the interest coverage of ICU MEDICAL ENTREPRISE FR... (0.2x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Umlaufvermögensbedarf und Zahlungsfristen

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 72 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 68 days. The company must finance 4 days of gap between collections and payments. Overall, WCR represents 206 days of revenue, i.e. 14.7 M€ to permanently finance. Over 2017-2024, WCR increased by +102%, requiring additional financing.

Operatives Working Capital (2024) ?
Operatives Working Capital
Definition
Besoin de financement généré par le cycle d'exploitation (stocks + créances - dettes fournisseurs).
Formel
Stocks + Créances clients - Dettes fournisseurs
Interpretation
Negativ = freigesetzte Liquidität
Positiv = Finanzierungsbedarf

14 666 705 €

Kundenforderungen (2024) ?
Kundenforderungen (Tage)
Definition
Durchschnittliche Zahlungsfrist für Kunden.
Formel
(Kundenforderungen / Umsatz inkl. MwSt.) x 360
Interpretation
< 45j : Gut
45-60j : Durchschnitt
> 60j : Lang

72 j

Lieferantenverbindlichkeiten (2024) ?
Lieferantenverbindlichkeiten (Tage)
Definition
Durchschnittliche Zahlungsfrist von Lieferanten.
Formel
(Lieferantenverbindlichkeiten / Einkäufe inkl. MwSt.) x 360
Interpretation
Je länger die Frist, desto besser für die Liquidität

68 j

Lagerumschlag (2024) ?
Lagerumschlag (Tage)
Definition
Durchschnittliche Lagerdauer für Waren oder Materialien.
Formel
(Vorräte / Einkaufskosten) x 360
Interpretation
Je niedriger das Verhältnis, desto schneller der Umschlag

0 j

Working Capital in Umsatztagen (2024) ?
Working Capital in Umsatztagen
Definition
Drückt den Betriebskapitalbedarf in Umsatztagen aus.
Formel
(BFR exploitation / CA) x 360
Interpretation
Je weniger Tage, desto besser das Working Capital Management

206 j

Entwicklung des Working Capital und der Zahlungsfristen
ICU MEDICAL ENTREPRISE FRANCE SAS

Positionnement de ICU MEDICAL ENTREPRISE FRANCE SAS dans son secteur

Vergleich mit der Branche Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Bewertungsschätzung

Based on 124 transactions of similar company sales (all years), the value of ICU MEDICAL ENTREPRISE FRANCE SAS is estimated at 2 138 156 € (range 1 104 930€ - 6 782 377€). With an EBITDA of 793 769€, the sector multiple of 0.7x is applied. The price/revenue ratio is 0.21x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
124 transactions
1104k€ 2138k€ 6782k€
2 138 156 € Range: 1 104 930€ - 6 782 377€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
793 769 € × 0.7x
Estimation 558 722 €
264 128€ - 2 033 545€
Revenue Multiple 30%
25 693 198 € × 0.21x
Estimation 5 471 993 €
2 967 332€ - 16 574 758€
Net Income Multiple 20%
1 321 931 € × 0.8x
Estimation 1 085 987 €
413 334€ - 3 965 887€

Bewertungsentwicklung

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare ICU MEDICAL ENTREPRISE FRANCE SAS with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about ICU MEDICAL ENTREPRISE FRANCE SAS

What is the revenue of ICU MEDICAL ENTREPRISE FRANCE SAS ?

The revenue of ICU MEDICAL ENTREPRISE FRANCE SAS in 2024 is 25.7 M€.

Is ICU MEDICAL ENTREPRISE FRANCE SAS profitable?

Yes, ICU MEDICAL ENTREPRISE FRANCE SAS generated a net profit of 1.3 M€ in 2024.

Where is the headquarters of ICU MEDICAL ENTREPRISE FRANCE SAS ?

The headquarters of ICU MEDICAL ENTREPRISE FRANCE SAS is located in RUNGIS (94150), in the department Val-de-Marne.

Where to find the tax return of ICU MEDICAL ENTREPRISE FRANCE SAS ?

The tax return of ICU MEDICAL ENTREPRISE FRANCE SAS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does ICU MEDICAL ENTREPRISE FRANCE SAS operate?

ICU MEDICAL ENTREPRISE FRANCE SAS operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.